Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months

Saydam G., HAZNEDAROĞLU İ. C., Temiz Y., Soysal T., Sucak G., TOMBULOĞLU M., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.19, sa.4, ss.195-204, 2009 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.4999/uhod.2009.19.09137
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.195-204
  • İstanbul Üniversitesi Adresli: Evet

Özet

This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72 +/- 171.29, 714.29 +/- 106.90, and 569.23 +/- 160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.